Select targeted therapies and monitor treatment response in advanced cancers

 

LiquidHALLMARKTM is a blood test that simultaneously detects multiple actionable somatic genetic alterations, microsatellite instability (MSI) and cancer-related viral targets in circulating cell-free tumor DNA. It is powered by Lucence’s patented molecular watermarking technology AmpliMARKTM that delivers ultra-deep sequencing for accurate results. This test targets breast, colon, lung and nasopharyngeal cancers in one test.

 Select targeted therapies and monitor treatment response in advanced cancers

LiquidHALLMARKTM is a blood test that simultaneously detect multiple actionable somatic genetic alterations, microsatellite instability (MSI) and cancer-related viral targets in circulating cell-free tumor DNA. It is powered by Lucence’s patented molecular watermarking technology AmpliMARKTM that delivers ultra-deep sequencing for accurate results. This test targets breast, colon, lung and nasopharyngeal cancers in one test.

OUR TECHNOLOGY

  • Identifies actionable somatic genetic alterations from tumor DNA circulating in blood
  • Includes MSI targets, which indicate that the tumor is more sensitive for immunotherapy
  • Covers cancer-associated viruses such as the Epstein-Barr virus (EBV) for better diagnosis and monitoring of Asian cancers
  • Targets the most common cancers including breast, colon and lung cancers
  • Ultra-deep sequencing powered by Lucence’s patented molecular watermarking technology AmpliMARKTM
  • Highly accurate with > 99% sensitivity and specificity to minimize false positive results

References

  1. Choudhury, Y. et al. J Clin Oncol, 36, 2018 (suppl; abstr e24107).
  2. Vo, J. H. et al. Sci. Rep. 6:13 (2016).
  3. Tan, M.H. and Vo, J. H. Patent Cooperation Treaty Application No. PCT/SG2016/050611 (2016).
  4. Choudhury, Y., Chen, H. and Tan, M. H. Singapore Patent Application No. 10201805450Y (2018).

OUR TECHNOLOGY

  • Identifies actionable somatic genetic alterations from tumor DNA circulating in blood
  • Includes MSI targets, which indicate that the tumor is more sensitive for immunotherapy
  • Covers cancer-associated viruses such as the Epstein-Barr virus (EBV) for better diagnosis and monitoring of Asian cancers
  • Targets the most common cancers including breast, colon and lung cancers
  • Ultra-deep sequencing powered by Lucence’s patented molecular watermarking technology AmpliMARK™
  • Highly accurate with > 99% sensitivity and specificity to minimize false positive results

References

    1. Choudhury, Y. et al. J Clin Oncol, 36, 2018 (suppl; abstr e24107).
    2. Vo, J. H. et al. Sci. Rep. 6:13 (2016).
    3. Tan, M.H. and Vo, J. H. Patent Cooperation Treaty Application No. PCT/SG2016/050611 (2016).
    4. Choudhury, Y., Chen, H. and Tan, M. H. Singapore Patent Application No. 10201805450Y (2018).

TEST SPECIFICATIONS

 

Methodology Ultra-Deep Sequencing Based on Lucence’s Patented Molecular Watermarking AmpliMARK™ Technology
Turnaround Time 7 Days for Core Report

2 Weeks for Extended Report

Targets 21 Genes, MSI, 2 Viral Targets
Analytical Limit of Detection 0.1%
Sample Requirements 3 Streck Tubes of Blood (22.5mL)

TEST SPECIFICATIONS

Methodology Ultra-Deep Sequencing Based on Lucence’s Patented Molecular Watermarking AmpliMARK™ Technology
Turnaround Time 7 Days for Core Report

2 Weeks for Extended Report

Targets 21 Genes, MSI, 2 Viral Targets
Analytical Limit of Detection 0.1%
Sample Requirements 3 Streck Tubes of Blood (22.5mL)

LIST OF CLINICALLY ACTIONABLE TARGETS

 

GENES*

 

AKT1 ALK# APC AR BRAF CDKN2A
CTNNB1 EGFR ERBB2 (HER2)# ESR1 GNAS KIT
KRAS MED12 MET# NRAS PIK3CA PTEN
SMAD4^ TP53^ VHL      

MSI

 

BAT25 BAT26 NR21 NR24 NR27 MONO27

VIRAL TARGETS

 

EBV BamHI-W EBV EBNA1

* Targeted regions selected to maximize detection of known hotspot mutations. List available on request.

# Detection of genetic variants and amplification.

^ Full coverage.

Mutant Allele Frequency 0.10% 1% 5%
Diagnostic Accuracy Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Single Nucleotide Variants > 62.5% > 99% > 99% > 99% > 99% > 99%
Indels > 99% > 99% > 99% > 99% > 99% > 99%
      • Sensitivity reported for true variants in the Horizon Discovery™ circulating cell-free DNA (cfDNA) standards
      • Specificity reported is the per-base specificity across the LiquidHALLMARK™ panel (detection of true negatives)
      • Results tested at the stated mutant allele frequencies of Horizon Discovery™ cfDNA standards
      • Clinical data published in 2018 American Society of Clinical Oncology Meeting
      • Terms of Use

LIST OF CLINICALLY

ACTIONABLE TARGETS

 

AKT1 ALK# APC AR BRAF CDKN2A
CTNNB1 EGFR ERBB2 (HER2)# ESR1 GNAS KIT
KRAS MED12 MET# NRAS PIK3CA PTEN
SMAD4^ TP53^ VHL

MSI

 

BAT25 BAT26 NR21 NR24 NR27 MONO27

VIRAL TARGETS

 

EBV BamHI-W EBV EBNA1

* Targeted regions selected to maximize detection of known hotspot mutations. List available on request.

# Detection of genetic variants and amplification.

^ Full coverage.

Mutant Allele Frequency at 0.1%
Diagnostic Accuracy Sensitivity Specificity
Single Nucleotide Variants > 62.5% > 99%
Indels > 99% > 99%
Mutant Allele Frequency at 1%
Diagnostic Accuracy Sensitivity Specificity
Single Nucleotide Variants > 99% > 99%
Indels > 99% > 99%
Mutant Allele Frequency at 5%
Diagnostic Accuracy Sensitivity Specificity
Single Nucleotide Variants > 99% > 99%
Indels > 99% > 99%
    • Sensitivity reported for true variants in the Horizon Discovery™ circulating cell-free DNA (cfDNA) standards
    • Specificity reported is the per-base specificity across the LiquidHALLMARK™ panel (detection of true negatives)
    • Results tested at the stated mutant allele frequencies of Horizon Discovery™ cfDNA standards
    • Clinical data published in 2018 American Society of Clinical Oncology Meeting
    • Terms of Use

ORDER A TEST

Please call our sales hotline +65 6592 5102 or email us at [email protected] to place an order or find out more about LiquidHALLMARKTM

ORDER A TEST

Please call our sales hotline +65 6592 5102 or email us at [email protected] to place an order or find out more about LiquidHALLMARKTM.